Biocon Ltd.

Biocon Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 20 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 June 2026, providing investors with the latest insights into the company’s performance and outlook.

With a decisive surge to Rs 440.3 on 26 Jun 2026, Biocon Ltd. has reached a fresh 52-week high, extending its impressive 31.79% return over the past year. This milestone comes amid a backdrop of strong technical momentum and a market environment where the Sensex trades near its recent peaks.

Biocon Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 13.5% increase in open interest in its derivatives segment, signalling heightened market activity and evolving investor positioning despite a modest price decline over recent sessions.

Biocon Ltd., a mid-cap leader in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 11.05% surge in open interest (OI) in its derivatives segment, signalling heightened market activity and evolving investor positioning. Despite a modest decline in the stock price over recent sessions, the spike in OI alongside robust volume patterns suggests strategic directional bets are being placed, warranting close attention from market participants and analysts alike.

Biocon Ltd., a mid-cap heavyweight in the Pharmaceuticals & Biotechnology sector, has witnessed a notable surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest decline in share price over the past two sessions, the stock remains close to its 52-week high, reflecting underlying bullish sentiment amid mixed volume and delivery trends.

Biocon Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 10.0% increase in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest price decline over the past two days, the surge in OI alongside robust futures and options volumes suggests evolving directional bets and a complex market outlook for this mid-cap stock.

Biocon Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy, reflecting significant improvements across technical indicators, financial trends, valuation metrics, and overall quality. This upgrade, announced on 20 May 2026, follows a robust quarter and sustained market outperformance, signalling renewed investor confidence in the mid-cap company’s prospects.

Biocon Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend. This change is supported by a confluence of positive signals across key technical indicators including MACD, Bollinger Bands, and moving averages, signalling renewed investor confidence and potential upside in the near term.

The 50-day moving average has crossed above the 200-day moving average for Biocon Ltd., signalling a golden cross on 20 May 2026. Yet, the broader technical and fundamental picture presents a nuanced view that tempers the enthusiasm often associated with this crossover.

With a decisive surge to Rs 436.8 on 20 May 2026, Biocon Ltd. has reached a fresh 52-week high, extending its impressive 30.38% gain over the past year against the Sensex’s decline of 7.21%. This milestone reflects a strong alignment of technical indicators and sustained price momentum that has propelled the stock well above key moving averages.

With a decisive surge to Rs 435.75 on 19 Jun 2026, Biocon Ltd. has reached a fresh 52-week high, extending its impressive 26.76% gain over the past year against the Sensex’s decline of 7.79%. This milestone reflects a strong alignment of technical indicators and sustained price momentum that has propelled the stock well above its key moving averages.

With a sustained five-day rally culminating in a fresh 52-week high of Rs 430.2 on 15 Jun 2026, Biocon Ltd. has demonstrated robust price momentum that outpaces its sector and the broader market.

Biocon Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 12 May 2026. This change reflects a nuanced improvement across multiple parameters including quality, valuation, financial trends, and technical indicators. The upgrade comes amid a backdrop of positive quarterly financial results, rising promoter confidence, and a shift in technical momentum, positioning the stock as a cautious but promising pick for investors.

Biocon Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish outlook. This change is underscored by a combination of bullish signals from key technical indicators such as MACD, Bollinger Bands, and On-Balance Volume (OBV), despite some mixed readings from moving averages and the KST oscillator. The stock’s recent price action and technical upgrades suggest cautious optimism for investors amid broader market headwinds.

Biocon Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. The stock has outperformed its sector peers with a 2.93% gain today, supported by strong volume and rising investor participation, suggesting potential directional bets emerging in the market.

Biocon Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. The stock outperformed its sector and broader indices, supported by robust volume and rising investor participation, suggesting a potential directional bias emerging among traders.